🇺🇸 GH — Guardant Health, Inc.

Salud Compra fuerte
← Volver

Precio actual

175,00 USD

Máx. histórico

187,22

29 días

Caída desde máximo

-6,53%

Rango 52 semanas

74,55 – 191,05

Variación hoy

+2,50%

Cierre anterior

170,73

Rango de hoy

167,31 – 178,38

Volumen hoy

1.720.775

Peor caída histórica

-91,03%

12/02/2021 → 19/04/2024

Recuperado en 881 días

Volatilidad anualizada ⓘ

67,35%

Información
Nombre completo
Guardant Health, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Diagnostics & Research
Empleados
2.490
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
202,24 USD (puede no estar actualizado)
Primera cotización
04/10/2018
Precio actualizado
hace 17 horas
Sobre la empresa

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/01/2022 71,89 73,65 69,42 70,10 -3,64% 5,88% 1.111.900
20/01/2022 73,36 77,14 72,32 72,75 +1,04% 6,57% 1.595.400
19/01/2022 72,73 74,96 71,11 72,00 -0,76% 5,29% 1.315.200
18/01/2022 75,94 76,21 71,90 72,55 -6,48% 5,68% 1.301.700
14/01/2022 78,38 79,24 74,48 77,58 -1,55% 6,07% 2.015.000
13/01/2022 85,18 85,89 78,48 78,80 -8,21% 8,70% 1.964.800
12/01/2022 91,20 92,90 85,17 85,85 -5,60% 8,48% 1.135.200
11/01/2022 92,37 94,55 88,49 90,94 -1,59% 6,56% 1.243.300
10/01/2022 86,08 92,93 85,31 92,41 +5,21% 8,85% 2.510.300
07/01/2022 90,60 93,10 87,42 87,83 -2,67% 6,27% 851.800
06/01/2022 88,27 92,20 84,50 90,24 +1,50% 8,72% 992.200
05/01/2022 97,09 100,00 88,63 88,91 -9,26% 11,71% 1.245.700
04/01/2022 101,13 102,85 93,55 97,98 -2,50% 9,20% 1.305.000
03/01/2022 99,71 101,72 98,13 100,49 +0,47% 3,60% 843.600
31/12/2021 100,55 102,04 99,80 100,02 -0,21% 2,23% 465.700
30/12/2021 96,09 101,77 96,09 100,23 +4,12% 5,91% 687.800
29/12/2021 97,05 97,96 95,55 96,26 +0,26% 2,48% 472.400
28/12/2021 95,44 99,08 94,97 96,01 +0,37% 4,31% 800.300
27/12/2021 98,00 98,49 95,41 95,66 -1,87% 3,14% 690.000
23/12/2021 100,32 100,52 95,61 97,48 -2,02% 4,89% 579.200
22/12/2021 100,63 102,68 98,53 99,49 -1,52% 4,12% 870.600
21/12/2021 99,86 102,00 97,80 101,03 +1,36% 4,21% 1.240.900
20/12/2021 101,25 103,16 98,87 99,67 -3,33% 4,24% 1.263.300
17/12/2021 97,58 103,92 94,83 103,10 +5,47% 9,32% 2.207.400
16/12/2021 96,73 98,93 95,11 97,75 +1,25% 3,95% 1.545.000
15/12/2021 92,00 96,87 90,18 96,54 +5,57% 7,27% 1.425.700
14/12/2021 90,57 94,35 89,02 91,45 -2,88% 5,88% 733.400
13/12/2021 93,50 97,62 90,07 94,16 +0,36% 8,07% 634.000
10/12/2021 95,59 97,65 93,57 93,82 -0,47% 4,27% 1.382.500
09/12/2021 97,00 97,17 93,34 94,26 -3,16% 3,95% 898.800